Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancerFactors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expressionDetermining the need for adjuvant chemotherapy and selection of chemotherapy agentsSelection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapyPotential use of preoperative CDK4/6 inhibitorsSequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutationOverview of first-line therapy for advanced HR+/HER2 breast cancerExpert opinion on selection of first-line therapy and factors to considerSelection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trialPresenters:Joyce O’Shaughnessy, MDCelebrating Women Chair in Breast Cancer ResearchBaylor University Medical CenterChair, Breast Disease CommitteeSarah Cannon Research InstituteTexas OncologyDallas, TexasSara A. Hurvitz, MD, FACPProfessor of MedicineHead, Division of Hematology and OncologyDepartment of Medicine, UW MedicineSenior Vice PresidentClinical Research DivisionFred Hutchinson Cancer CenterSeattle, WashingtonErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchInstitute PhysicianDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program: https://bit.ly/3XZKp8f

There are no comments yet.

Please log in to write the first comment.